helicobacter pylori infection
Conditions
Interventions
Keverprazan Hydrochloride Tablets dual therapy Ten days group:Keverprazan Hydrochloride Tablets 20mg bid and Amoxicillin 1g tid were administered for 10 days
Keverprazan Hydrochloride Tablets dual therapy fourteen days group:Keverprazan Hydrochloride Tablets 20mg bid and Amoxicillin 1g tid were administered for 14days
Keverprazan Hydrochloride Tablets quadruple therapy Ten days group:Keverprazan Hydrochloride Tablets 20mg bid, and Bismuth agent quadruple scheme (1 g amoxicillin and clarithromycin 500 mg, bismuth po
Sponsors
Shenzhen Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) 18 age 75 years old or less, or less gender not limited; 2) Positive test for Helicobacter pylori (Hp) (¹³ C-urea breath test, monoclonal stool antigen test, histological test, rapid urease test or serological test, any two positive results); 3) Always not received Hp eradication therapy; 4) Can independently accomplish the subjects diary card record of the subjects; 5) Subjects who fully understood the content of the trial, volunteered to participate in the trial and were able to complete the trial process, and signed the informed consent
Exclusion criteria
Exclusion criteria: 1) Into the group 2 weeks before used acid suppression drugs, such as proton pump inhibitors, competitive acid potassium ion blockers, histamine H2 receptor antagonist, etc., or into the group of four weeks before used antibiotics, bismuth agent, antimicrobial effect of traditional Chinese medicine; 2) Subjects who have undergone or are scheduled to undergo surgery affecting gastric acid secretion (e.g., upper gastrointestinal resection, vagotomy, etc.); 3) Into the group of the first six months of endoscopy confirmed patients with atrophic gastritis, active peptic ulcer, the digestive tract tumor; 4) Before or are currently Zolling - Ellison syndrome (zhuo - ai syndrome) or other excessive gastric acid secretion disease history subjects; 5) Serious systemic diseases, major organ diseases such as heart, lung, brain diseases, liver and kidney dysfunction, malignant tumors or other diseases; 6) Known to be allergic to caprasian, bismuth, clarithromycin or amoxicillin and related excipients (such as mannitol, microcrystalline cellulose, cross-linked povidone, hydroxypropyl cellulose, magnesium stearate, etc.); 7) Pregnant or lactating women; 8) Long-term alcohol or any other increase in risk treatment; 9) Not suitable for other participants' 9) researchers say.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate of Hp; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse event rate; | — |
Countries
China
Contacts
Public ContactYe Chen
Shenzhen Hospital of Southern Medical University
Outcome results
None listed